GLOBAL PLASMA FRACTIONATION & DERIVATIVES MARKET (2026 - 2030)

In 2025, the Plasma Fractionation & Derivatives Market was valued at approximately USD 40.30 Billion. It is projected to grow at a CAGR of around 10% during the forecast period of 2026–2030, reaching an estimated USD 64.90 Billion by 2030.

The global plasma fractionation & derivatives market is the process of collecting, processing, separating, and commercializing human plasma-derived therapeutic proteins. These products are used to treat immune deficiencies, bleeding disorders, neurological conditions, liver complications, and critical care requirements where effective alternatives might not be available. The market comprises completed plasma-derived therapies, distribution channels, and demand in institutions of both acute and specialty care. It does not cover complete blood transfusion services, routine tests, or recombinant therapies created without the use of plasma.

The market has evolved in a significant way over the past couple of years. Demand has extended past the conventional applications of hematology to include neurology, immunology, and treatment of chronic diseases, putting strain on world supply chains. Meanwhile, manufacturers have increased the capacity of collections, invested in modern fractionation plants, and enhanced purification technologies to increase yields and product consistency. There has also been an increase in regulatory scrutiny, whereby the focus has been on the safety of donors, traceability, quality systems, and continuity of supply. In other areas, the healthcare systems are reevaluating procurement models to achieve reliable access to the necessary therapies.

To the decision-makers, the market has demanded more stringent planning and risk management. The mix of products is more important than just the volume; some therapies have higher margins, tighter supply, or are more readily adopted clinically. Regional strategy is also critical as the pricing, reimbursement, and reliance on imports differ greatly. Buyers, investors, and suppliers need to consider capacity schedules, channel realignment, and market expansion in areas of treatment. Companies that comprehend these moving parts can enhance sourcing resilience, allocate capital in a superior fashion, and seize growth in a market characterized by medical necessity and operational complexity.

Key Market Insights

• Fractionation of domestic plasma is only done in 56 out of 171 countries, revealing gaps in supply.
• All plasma-derived products are imported from 91 countries, which increases the risks of cross-border dependence.
• The 118.5 million global blood donations are distributed 40% by countries with high incomes.
• The low-income countries receive fewer than 5 donations per 1,000 residents.
• Depth is demonstrated in high-income countries, which have 31 donations per 1,000 people.
• The 2024 65-plus population of the Asia Pacific was 325,903,549, which hastened the demand for therapy.
• In 2024, the 65-plus share is at 7% in India, indicating long-tail growth.
• The 65-plus share in China stood at 15% in 2024 with the growth of specialty demand.
• In 2024, Japan had a 65-plus share of 30% and continues to use premiums.
• In 2024, the world population was 8.2 billion, increasing the number of patients.
• In 2024, the number of individuals above 65 years old was 703 million worldwide.
• By 2080, individuals older than 65 years of age will be more numerous than children below 18 years of age.
• There will be an increment of approximately 8% growth of pharmacy expenditure, which will strain reimbursement budgets.
• In 2025 guidance expanded the toll-fractionation alternatives, enabling nations to commercialize plasma inside their own nations.

Research Methodology

Scope & definitions

• Covers revenue generated from plasma fractionation and plasma-derived therapeutics including immunoglobulins, albumin, coagulation factors, protease inhibitors, fibrinogen concentrates, and related derivatives.
• Excludes whole blood banking, transfusion services, diagnostics, devices, and non-plasma recombinant biologics.
• Geography: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa; historical review, base year, and forecast period defined in-report.
• Standardized segmentation, data dictionary, and manufacturer-level mapping applied to prevent overlap or double counting.

Evidence collection (primary + secondary)

• Primary interviews across fractionators, contract manufacturers, distributors, hospitals, specialty clinics, clinicians, procurement leaders, and industry experts.
• Secondary sources include annual reports, investor filings, company presentations, product labels, tender databases, trade data, WHO, EMA, FDA, and relevant regulators/standards bodies/industry associations specific to Global Plasma Fractionation & Derivatives Market (named in-report).
• Key claims are supported with verifiable sources and source-linked evidence inside the report.

Triangulation & validation

• Market size built using bottom-up company/product revenue aggregation and top-down demand modeling by therapy use, patient pool, and regional utilization.
• Outputs reconciled to audited financial disclosures where applicable.
• Conflicting-source resolution, outlier testing, interview revalidation, and bias controls applied.

Presentation & auditability

• Deliverables include transparent assumptions, formulas, forecast drivers, sensitivity checks, and segment totals that reconcile.
• Source logs, calculation trails, and citation-ready references ensure decision-grade traceability.

Global Plasma Fractionation & Derivatives Market Drivers

Networks of automated plasma collection increase supply resilience.

Manufacturers and healthcare systems are hastening automated plasma collection models to enhance donor throughput, screening consistency, and scheduling efficiency. The contemporary centers are becoming more and more equipped with interconnected devices, digital intake processes, and predictive staffing solutions that decrease wait time and increase the reliability of collections. These upgrades assist in the stabilization of raw plasma supply, which is a very important aspect in the planning of derivative production.

Fractionation productivity in the world is being enhanced by smart manufacturing platforms.

Manufacturers are automating the process of fractionation by introducing robotization, new sensors, and digital twins, as well as real-time quality control. Such intelligent manufacturing systems are useful in the optimization of yields, the reduction of batch deviations, and the performance enhancement of compliance in highly regulated environments. Complex therapeutic portfolios are also enhanced with automated material handling and process controls through analytics.

The access to therapy is redefined by digital specialty distribution models.

The distribution channels are also changing because the healthcare providers are requiring quicker delivery, increased inventory control, and enhanced security in handling the specialty biologics. Companies are implementing merged ordering portals, cold-chain management tools, and automated replenishment systems that enhance continuity to the hospitals, clinics, and home-based care models. These technologies minimize the exposure to stockouts and help maintain a closer control over sensitive therapies.

Global Plasma Fractionation & Derivatives Market Restraints

There is continuous pressure on the market due to the lack of plasma collection capacity, the long fractionation process, and the intense regulation that impedes new entry into the market. Payers' scrutiny of prices squeezes the margins, and the cold-chain logistics increase the operating risk in remote markets. Innovation is often pushed aside by budget considerations, and hospitals frequently do not adopt premium therapy.

Global Plasma Fractionation & Derivatives Market Opportunities

The rising prospects are based on growing models of home infusion, increasing the number of diagnoses of immune and neurologic conditions, and rare disease premium therapies. The manufacturers can create value by expanding plasma collection, optimizing yield, and planning supply digitally. Previous markets are emerging markets with untapped demand as reimbursement increases and the capacity of hospitals increases. Access can be expanded by partnering with specialty clinics and online fulfillment channels.

How this market works end-to-end

1. Donor Plasma Collection
   Human plasma is collected through approved centers. Collection scale and donor retention influence future supply.
2. Testing And Screening
   Plasma undergoes strict safety testing. Failure rates or tighter standards can reduce usable volume.
3. Fractionation Process
   Collected plasma is separated into proteins. This creates inputs for immunoglobulins, albumin, coagulation factors, and other derivatives.
4. Purification And Fill
   Products are purified, formulated, packaged, and prepared for regulated release.
5. Regulatory Release
   Each region applies approvals, batch release, and quality controls. Timing varies by market.
6. Channel Allocation
   Products move through direct tenders, retail pharmacies, online pharmacies where allowed, and specialty supply routes.
7. Clinical Demand Use
   Hospitals, specialty clinics, and research institutions purchase based on treatment need and reimbursement rules.
8. Regional Rebalancing
   North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa each show different supply-demand dynamics.

Why this market matters now

The strategic issue is supply continuity under constraint. Demand remains durable, but supply expansion is slow. That mismatch creates pressure across pricing, tenders, and patient access.

Many buyers still treat plasma therapies as routine procurement categories. That is risky. Plasma markets depend on donor ecosystems, regulated manufacturing, cold-chain reliability, and cross-border approvals. A disruption in one node can affect many countries.

Capital decisions also matter now. New capacity can improve resilience, but timing errors can trap capital if product mix shifts. Buyers need clarity on which therapies are structurally growing versus temporarily tight.

What matters most when evaluating claims in this market

The decision lens

1. Define Boundary Clearly
   Confirm whether you need therapy revenues, production capacity, or procurement pricing.
2. Check Product Mix
   Compare immunoglobulins, albumin, coagulation factors, and niche derivatives separately.
3. Stress Supply Base
   Review supplier concentration, donor exposure, and manufacturing redundancy.
4. Test Regional Logic
   Assess demand by geography, reimbursement model, and import dependence.
5. Model Price Paths
   Separate tender pricing, private channel pricing, and emergency spot buys.
6. Verify Timing Risks
   Check approval timelines, expansion ramp-up, and contract renewal cycles.
7. Challenge Assumptions
   Ask vendors what would break their forecast.

The contrarian view

A larger market does not always mean an easier market. Growth can come with tighter supply and harder procurement.

Many estimates double count value by mixing plasma collection revenue with finished therapy sales.

Some analysts overuse patient prevalence data while ignoring treatment access limits.

Global averages hide local reality. One region may be oversupplied while another faces shortage.

Not every capacity announcement changes the market. Execution matters more than headlines.

Practical implications by stakeholder

• 1. Manufacturers
• Prioritize profitable product mix, not just volume.
• Build multi-region resilience into sourcing plans.
  2. Hospitals

• Secure supply contracts earlier for critical therapies.
• Monitor substitution risks and formulary flexibility.
  3. Distributors

• Strengthen cold-chain and inventory visibility.
• Prepare for sudden regional reallocation requests.
  4. Investors

• Focus on execution quality and capacity ramp realism.
• Separate durable demand from temporary scarcity gains.
  5. Policy Makers

• Encourage safe donor ecosystems.
• Reduce approval bottlenecks without lowering standards.

Procurement Teams

• Compare landed cost, not unit price only.
• Audit concentration risk across suppliers.

GLOBAL PLASMA FRACTIONATION & DERIVATIVES MARKET

Global Plasma Fractionation & Derivatives Market Segmentation

Global Plasma Fractionation & Derivatives Market – By Product Type
• Introduction/Key Findings
• Immunoglobulins (IVIG & SCIG)
• Albumin
• Coagulation Factor Concentrates
• Protease Inhibitors (e.g., Alpha-1 Antitrypsin)
• Fibrinogen Concentrates
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Immunoglobulins have a 46.2% share in 2025 with the help of chronic immune deficiency treatment and the growing use of SCIG to maintain pricing strength and revenue leadership over albumin and factors worldwide, currently still on a clear lead.

Protease inhibitors are increasing at the highest rate of 9.8% CAGR as alpha-1 antitrypsin diagnosis gains momentum throughout the world. Specialty respiratory prescribing gains margins, whilst a 7.3% share gives plenty of headroom to penetrate through 2030 in most of the underserved therapy channels currently.

Global Plasma Fractionation & Derivatives Market – By Application
• Introduction/Key Findings
• Neurology
• Immunology
• Hematology
• Critical Care & Pulmonology
• Hepatology
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Immunology dominates the top 38.7% share since immunoglobulin treatment is still necessary in primary and secondary deficiencies across the world. Recurring dosing ensures stable revenues, and deep reimbursement in developed countries consolidates the purchasing habits of buyers every year, consistently every year, everywhere now.

Neurology has the highest growth rate at 10.2% CAGR, with CIDP and myasthenia diagnoses growing more and more. Greater clinician confidence increases IVIG usage, and an 18.4 share provides significant expansion potential in the outpatient care environment today in most advanced and emerging markets worldwide.

Global Plasma Fractionation & Derivatives Market – By End User

• Introduction/Key Findings
• Hospitals
• Specialty Clinics
• Academic & Research Institutes
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Global Plasma Fractionation & Derivatives Market – By Distribution Channel
• Introduction/Key Findings
• Direct Tender Sales
• Retail Pharmacies
• Online Pharmacies
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Global Plasma Fractionation & Derivatives Market– Regional Analysis

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America has a 41% market share with robust plasma collection networks, premium therapy uptake, and wide access to reimbursement. Integrated supply chains enhance access and uptake of premium therapy and high revenue intensity regionally today for all participants.

Asia Pacific is the fastest expanding region with a 10.6% CAGR due to China, Japan, India, and South Korea. Expanding diagnosis and healthcare access support its 27 percent share with a reduction in the historical gaps with steady progress with each major urban treatment center each year, henceforth.

Latest Market News

On Mar 10, 2026, CSL commenced a $1.5 billion expansion of plasma-derived therapies in Kankakee, Illinois, and commercial operations are expected in 2031. It was announced March 10, 2026, that the project would generate at least 300 new jobs, which would enhance the ability of North American immunoglobulin and albumin to supply the market.

In 2025, Grifols said it would have 2026 revenue of EUR 7,524 million, and its net profit would increase more than 7 percent per year, and net profit more than doubled to EUR 402 million. The management also steered 2026 adjusted EBITDA growth of over 25%, which is an indicator of an increase in operating leverage in plasma derivatives, on Feb 26, 2026.

Grifols' Refinancing, April 1, 2026: Grifols announced a much larger EUR 3 billion refinancing of Term Loan B that fully covered all the 2027 debt maturities. The move of April 01, 2026, enhanced the flexibility of the balance sheet in order to invest further in plasma collection and fractionation operations.

Dec 19, 2025, Grifols was granted U.S. FDA approval of FESILTY human fibrinogen concentrate, a new product in its portfolio of hospital bleeding management products. On Dec 19, 2025, the approval helped the company to increase its presence in high-value coagulation therapies and expand its U.S. plasma derivatives products.

On Dec 16, 2025, Grifols reported approval of the entire value chain of Grifols Egypt by the European Medicines Agency. The milestone will enable Egypt to move towards self-sufficiency and increase access to plasma-derived medicines throughout the region to 2 interconnected continents, Africa and the Middle East, by Dec 16, 2025.

On Nov 18, 2025, CSL invested approximately 1.5 billion in the next 5 years to increase the manufacturing capacity of plasma in the U.S. The investment, placed Nov 18, 2025, was aimed at strengthening the domestic supply of immunoglobulin therapies in response to increasing clinical need over the long term.

The 2025 ISPE Facility of the Year overall award was awarded to CSL in 2025 for its Project Aurora plant in Australia. The site expanded processing capacity to over 10 million liters of plasma each year on October 31, 2025, and raised local capacity by 9 times compared to earlier.

Takeda, Dec 27, 2024: Takeda received HYQVIA 10% approval in Japan to treat agammaglobulinemia and hypogammaglobulinemia, the first facilitated SCIG in the category in the country. The therapy will be Dec 27, 2024, with 2 vials/treatment set and less frequent dosing as compared to the traditional subcutaneous doses.

Key Players

1. CSL Behring
2. Grifols S.A.
3. Takeda Pharmaceutical Company Limited
4. Octapharma AG
5. Kedrion S.p.A.
6. Bio Products Laboratory Ltd.
7. LFB S.A.
8. Sanquin Plasma Products B.V.
9. China Biologic Products Holdings, Inc.
10. GC Biopharma Corp.

    In 2025, the Plasma Fractionation & Derivatives Market was valued at approximately USD 40.30 Billion. It is projected to grow at a CAGR of around 10% during the forecast period of 2026–2030, reaching an estimated USD 64.90 Billion by 2030.

    The global plasma fractionation & derivatives market is the process of collecting, processing, separating, and commercializing human plasma-derived therapeutic proteins. These products are used to treat immune deficiencies, bleeding disorders, neurological conditions, liver complications, and critical care requirements where effective alternatives might not be available. The market comprises completed plasma-derived therapies, distribution channels, and demand in institutions of both acute and specialty care. It does not cover complete blood transfusion services, routine tests, or recombinant therapies created without the use of plasma.

    The market has evolved in a significant way over the past couple of years. Demand has extended past the conventional applications of hematology to include neurology, immunology, and treatment of chronic diseases, putting strain on world supply chains. Meanwhile, manufacturers have increased the capacity of collections, invested in modern fractionation plants, and enhanced purification technologies to increase yields and product consistency. There has also been an increase in regulatory scrutiny, whereby the focus has been on the safety of donors, traceability, quality systems, and continuity of supply. In other areas, the healthcare systems are reevaluating procurement models to achieve reliable access to the necessary therapies.

    To the decision-makers, the market has demanded more stringent planning and risk management. The mix of products is more important than just the volume; some therapies have higher margins, tighter supply, or are more readily adopted clinically. Regional strategy is also critical as the pricing, reimbursement, and reliance on imports differ greatly. Buyers, investors, and suppliers need to consider capacity schedules, channel realignment, and market expansion in areas of treatment. Companies that comprehend these moving parts can enhance sourcing resilience, allocate capital in a superior fashion, and seize growth in a market characterized by medical necessity and operational complexity.

    

    Key Market Insights

11. Fractionation of domestic plasma is only done in 56 out of 171 countries, revealing gaps in supply.
12. All plasma-derived products are imported from 91 countries, which increases the risks of cross-border dependence.
13. The 118.5 million global blood donations are distributed 40% by countries with high incomes.
14. The low-income countries receive fewer than 5 donations per 1,000 residents.
15. Depth is demonstrated in high-income countries, which have 31 donations per 1,000 people.
16. The 2024 65-plus population of the Asia Pacific was 325,903,549, which hastened the demand for therapy.
17. In 2024, the 65-plus share is at 7% in India, indicating long-tail growth.
18. The 65-plus share in China stood at 15% in 2024 with the growth of specialty demand.
19. In 2024, Japan had a 65-plus share of 30% and continues to use premiums.
20. In 2024, the world population was 8.2 billion, increasing the number of patients.
21. In 2024, the number of individuals above 65 years old was 703 million worldwide.
22. By 2080, individuals older than 65 years of age will be more numerous than children below 18 years of age.
23. There will be an increment of approximately 8% growth of pharmacy expenditure, which will strain reimbursement budgets.
24. In 2025 guidance expanded the toll-fractionation alternatives, enabling nations to commercialize plasma inside their own nations.

25. 

    Research Methodology

    Scope & definitions

26. Covers revenue generated from plasma fractionation and plasma-derived therapeutics including immunoglobulins, albumin, coagulation factors, protease inhibitors, fibrinogen concentrates, and related derivatives.
27. Excludes whole blood banking, transfusion services, diagnostics, devices, and non-plasma recombinant biologics.
28. Geography: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa; historical review, base year, and forecast period defined in-report.
29. Standardized segmentation, data dictionary, and manufacturer-level mapping applied to prevent overlap or double counting.

30. Evidence collection (primary + secondary)

31. Primary interviews across fractionators, contract manufacturers, distributors, hospitals, specialty clinics, clinicians, procurement leaders, and industry experts.
32. Secondary sources include annual reports, investor filings, company presentations, product labels, tender databases, trade data, WHO, EMA, FDA, and relevant regulators/standards bodies/industry associations specific to Global Plasma Fractionation & Derivatives Market (named in-report).
33. Key claims are supported with verifiable sources and source-linked evidence inside the report.

34. Triangulation & validation

35. Market size built using bottom-up company/product revenue aggregation and top-down demand modeling by therapy use, patient pool, and regional utilization.
36. Outputs reconciled to audited financial disclosures where applicable.
37. Conflicting-source resolution, outlier testing, interview revalidation, and bias controls applied.

38. Presentation & auditability

39. Deliverables include transparent assumptions, formulas, forecast drivers, sensitivity checks, and segment totals that reconcile.
40. Source logs, calculation trails, and citation-ready references ensure decision-grade traceability.

41. 

    Global Plasma Fractionation & Derivatives Market Drivers

    Networks of automated plasma collection increase supply resilience.

    Manufacturers and healthcare systems are hastening automated plasma collection models to enhance donor throughput, screening consistency, and scheduling efficiency. The contemporary centers are becoming more and more equipped with interconnected devices, digital intake processes, and predictive staffing solutions that decrease wait time and increase the reliability of collections. These upgrades assist in the stabilization of raw plasma supply, which is a very important aspect in the planning of derivative production.

    Fractionation productivity in the world is being enhanced by smart manufacturing platforms.

    Manufacturers are automating the process of fractionation by introducing robotization, new sensors, and digital twins, as well as real-time quality control. Such intelligent manufacturing systems are useful in the optimization of yields, the reduction of batch deviations, and the performance enhancement of compliance in highly regulated environments. Complex therapeutic portfolios are also enhanced with automated material handling and process controls through analytics.

    The access to therapy is redefined by digital specialty distribution models.

    The distribution channels are also changing because the healthcare providers are requiring quicker delivery, increased inventory control, and enhanced security in handling the specialty biologics. Companies are implementing merged ordering portals, cold-chain management tools, and automated replenishment systems that enhance continuity to the hospitals, clinics, and home-based care models. These technologies minimize the exposure to stockouts and help maintain a closer control over sensitive therapies.

    Global Plasma Fractionation & Derivatives Market Restraints

    There is continuous pressure on the market due to the lack of plasma collection capacity, the long fractionation process, and the intense regulation that impedes new entry into the market. Payers' scrutiny of prices squeezes the margins, and the cold-chain logistics increase the operating risk in remote markets. Innovation is often pushed aside by budget considerations, and hospitals frequently do not adopt premium therapy.

    Global Plasma Fractionation & Derivatives Market Opportunities

    The rising prospects are based on growing models of home infusion, increasing the number of diagnoses of immune and neurologic conditions, and rare disease premium therapies. The manufacturers can create value by expanding plasma collection, optimizing yield, and planning supply digitally. Previous markets are emerging markets with untapped demand as reimbursement increases and the capacity of hospitals increases. Access can be expanded by partnering with specialty clinics and online fulfillment channels.

    How this market works end-to-end

42. Donor Plasma Collection
    Human plasma is collected through approved centers. Collection scale and donor retention influence future supply.
43. Testing And Screening
    Plasma undergoes strict safety testing. Failure rates or tighter standards can reduce usable volume.
44. Fractionation Process
    Collected plasma is separated into proteins. This creates inputs for immunoglobulins, albumin, coagulation factors, and other derivatives.
45. Purification And Fill
    Products are purified, formulated, packaged, and prepared for regulated release.
46. Regulatory Release
    Each region applies approvals, batch release, and quality controls. Timing varies by market.
47. Channel Allocation
    Products move through direct tenders, retail pharmacies, online pharmacies where allowed, and specialty supply routes.
48. Clinical Demand Use
    Hospitals, specialty clinics, and research institutions purchase based on treatment need and reimbursement rules.
49. Regional Rebalancing
    North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa each show different supply-demand dynamics.

50. Why this market matters now

    The strategic issue is supply continuity under constraint. Demand remains durable, but supply expansion is slow. That mismatch creates pressure across pricing, tenders, and patient access.

    Many buyers still treat plasma therapies as routine procurement categories. That is risky. Plasma markets depend on donor ecosystems, regulated manufacturing, cold-chain reliability, and cross-border approvals. A disruption in one node can affect many countries.

    Capital decisions also matter now. New capacity can improve resilience, but timing errors can trap capital if product mix shifts. Buyers need clarity on which therapies are structurally growing versus temporarily tight.

    What matters most when evaluating claims in this market

    Claim type	What good proof looks like	What often goes wrong
    Fast market growth	Product-level demand by therapy and region	Uses broad healthcare growth as proxy
    Strong supply outlook	New capacity with realistic ramp timelines	Counts announced plants as live output
    Stable pricing	Contract mix and reimbursement trends	Assumes list price equals realized price
    Low risk sourcing	Multi-region supply footprint	Ignores donor concentration
    High margin segment	Mix-adjusted product economics	Blends low and high value therapies

    The decision lens

51. Define Boundary Clearly
    Confirm whether you need therapy revenues, production capacity, or procurement pricing.
52. Check Product Mix
    Compare immunoglobulins, albumin, coagulation factors, and niche derivatives separately.
53. Stress Supply Base
    Review supplier concentration, donor exposure, and manufacturing redundancy.
54. Test Regional Logic
    Assess demand by geography, reimbursement model, and import dependence.
55. Model Price Paths
    Separate tender pricing, private channel pricing, and emergency spot buys.
56. Verify Timing Risks
    Check approval timelines, expansion ramp-up, and contract renewal cycles.
57. Challenge Assumptions
    Ask vendors what would break their forecast.

58. The contrarian view

    A larger market does not always mean an easier market. Growth can come with tighter supply and harder procurement.

    Many estimates double count value by mixing plasma collection revenue with finished therapy sales.

    Some analysts overuse patient prevalence data while ignoring treatment access limits.

    Global averages hide local reality. One region may be oversupplied while another faces shortage.

    Not every capacity announcement changes the market. Execution matters more than headlines.

    Practical implications by stakeholder

59. 1. Manufacturers
60. Prioritize profitable product mix, not just volume.
61. Build multi-region resilience into sourcing plans.
    2. Hospitals
62. Secure supply contracts earlier for critical therapies.
63. Monitor substitution risks and formulary flexibility.
    3. Distributors
64. Strengthen cold-chain and inventory visibility.
65. Prepare for sudden regional reallocation requests.
    4. Investors
66. Focus on execution quality and capacity ramp realism.
67. Separate durable demand from temporary scarcity gains.
    5. Policy Makers
68. Encourage safe donor ecosystems.
69. Reduce approval bottlenecks without lowering standards.

70. Procurement Teams

71. Compare landed cost, not unit price only.
72. Audit concentration risk across suppliers.

73. Global Plasma Fractionation & Derivatives Market Segmentation

    Global Plasma Fractionation & Derivatives Market – By Product Type
    • Introduction/Key Findings
    • Immunoglobulins (IVIG & SCIG)
    • Albumin
    • Coagulation Factor Concentrates
    • Protease Inhibitors (e.g., Alpha-1 Antitrypsin)
    • Fibrinogen Concentrates
    • Others
    • Y-O-Y Growth Trend & Opportunity Analysis

    Immunoglobulins have a 46.2% share in 2025 with the help of chronic immune deficiency treatment and the growing use of SCIG to maintain pricing strength and revenue leadership over albumin and factors worldwide, currently still on a clear lead.

    Protease inhibitors are increasing at the highest rate of 9.8% CAGR as alpha-1 antitrypsin diagnosis gains momentum throughout the world. Specialty respiratory prescribing gains margins, whilst a 7.3% share gives plenty of headroom to penetrate through 2030 in most of the underserved therapy channels currently.

    Global Plasma Fractionation & Derivatives Market – By Application
    • Introduction/Key Findings
    • Neurology
    • Immunology
    • Hematology
    • Critical Care & Pulmonology
    • Hepatology
    • Others
    • Y-O-Y Growth Trend & Opportunity Analysis

    Immunology dominates the top 38.7% share since immunoglobulin treatment is still necessary in primary and secondary deficiencies across the world. Recurring dosing ensures stable revenues, and deep reimbursement in developed countries consolidates the purchasing habits of buyers every year, consistently every year, everywhere now.

    Neurology has the highest growth rate at 10.2% CAGR, with CIDP and myasthenia diagnoses growing more and more. Greater clinician confidence increases IVIG usage, and an 18.4 share provides significant expansion potential in the outpatient care environment today in most advanced and emerging markets worldwide.

    Global Plasma Fractionation & Derivatives Market – By End User

    
    • Introduction/Key Findings
    • Hospitals
    • Specialty Clinics
    • Academic & Research Institutes
    • Others
    • Y-O-Y Growth Trend & Opportunity Analysis

    Global Plasma Fractionation & Derivatives Market – By Distribution Channel
    • Introduction/Key Findings
    • Direct Tender Sales
    • Retail Pharmacies
    • Online Pharmacies
    • Others
    • Y-O-Y Growth Trend & Opportunity Analysis

    Global Plasma Fractionation & Derivatives Market– Regional Analysis

74. North America
75. Europe
76. Asia-Pacific
77. Latin America
78. Middle East and Africa

79. North America has a 41% market share with robust plasma collection networks, premium therapy uptake, and wide access to reimbursement. Integrated supply chains enhance access and uptake of premium therapy and high revenue intensity regionally today for all participants.

    Asia Pacific is the fastest expanding region with a 10.6% CAGR due to China, Japan, India, and South Korea. Expanding diagnosis and healthcare access support its 27 percent share with a reduction in the historical gaps with steady progress with each major urban treatment center each year, henceforth.

    

    Latest Market News

    On Mar 10, 2026, CSL commenced a $1.5 billion expansion of plasma-derived therapies in Kankakee, Illinois, and commercial operations are expected in 2031. It was announced March 10, 2026, that the project would generate at least 300 new jobs, which would enhance the ability of North American immunoglobulin and albumin to supply the market.

    In 2025, Grifols said it would have 2026 revenue of EUR 7,524 million, and its net profit would increase more than 7 percent per year, and net profit more than doubled to EUR 402 million. The management also steered 2026 adjusted EBITDA growth of over 25%, which is an indicator of an increase in operating leverage in plasma derivatives, on Feb 26, 2026.

    Grifols' Refinancing, April 1, 2026: Grifols announced a much larger EUR 3 billion refinancing of Term Loan B that fully covered all the 2027 debt maturities. The move of April 01, 2026, enhanced the flexibility of the balance sheet in order to invest further in plasma collection and fractionation operations.

    Dec 19, 2025, Grifols was granted U.S. FDA approval of FESILTY human fibrinogen concentrate, a new product in its portfolio of hospital bleeding management products. On Dec 19, 2025, the approval helped the company to increase its presence in high-value coagulation therapies and expand its U.S. plasma derivatives products.

    On Dec 16, 2025, Grifols reported approval of the entire value chain of Grifols Egypt by the European Medicines Agency. The milestone will enable Egypt to move towards self-sufficiency and increase access to plasma-derived medicines throughout the region to 2 interconnected continents, Africa and the Middle East, by Dec 16, 2025.

    On Nov 18, 2025, CSL invested approximately 1.5 billion in the next 5 years to increase the manufacturing capacity of plasma in the U.S. The investment, placed Nov 18, 2025, was aimed at strengthening the domestic supply of immunoglobulin therapies in response to increasing clinical need over the long term.

    The 2025 ISPE Facility of the Year overall award was awarded to CSL in 2025 for its Project Aurora plant in Australia. The site expanded processing capacity to over 10 million liters of plasma each year on October 31, 2025, and raised local capacity by 9 times compared to earlier.

    Takeda, Dec 27, 2024: Takeda received HYQVIA 10% approval in Japan to treat agammaglobulinemia and hypogammaglobulinemia, the first facilitated SCIG in the category in the country. The therapy will be Dec 27, 2024, with 2 vials/treatment set and less frequent dosing as compared to the traditional subcutaneous doses.

    Key Player

80. CSL Behring

81. Grifols S.A.
82. Takeda Pharmaceutical Company Limited
83. Octapharma AG
84. Kedrion S.p.A.
85. Bio Products Laboratory Ltd.
86. LFB S.A.
87. Sanquin Plasma Products B.V.
88. China Biologic Products Holdings, Inc.
89. GC Biopharma Corp.